RxDoctor Payments Data

William King, MD

Nephrology · Henderson, NVNPI 1467433961

Payments from drug & device makers

$1,623in general payments, 2019–2025

Across 99 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$537
  • AstraZeneca$248
  • Amgen$186
  • Otsuka America Pharmaceutical, Inc.$164
  • ANI Pharmaceuticals, Inc.$135
  • Bayer$114
  • plus $239 from 8 others

What the payments were for

  • Food & beverage$1,623100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,623 in reported general payments places this provider in the 45th percentile of 125 nephrology providers in Nevada.

See all nephrology providers in Nevada

Medicare billing

Part B allowed, 2024
$169,096
Medicare patients
383
Services billed
1,509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol193$136,167
JardianceEmpagliflozin79$56,859
VeltassaPatiromer Calcium Sorbitex20$21,959
DapagliflozinDapagliflozin Propanediol11$9,923
Amlodipine Besylate84$451
Calcium Acetate14$447
Famotidine29$334
Calcitriol15$286
Clonidine Hcl18$244
Furosemide34$221
Potassium Chloride11$221
Allopurinol17$203
Hydralazine Hcl21$151
Prednisone12$119
Spironolactone12$111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$248$136,167193 claims
ANI Pharmaceuticals, Inc.Valsartan$135$3414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 125 nephrology providers in Nevada.

Other nephrology in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →